The anti-cancer effect of niclosamide was mediated by the downregulation of the Wnt/β-catenin signaling, which downregulated β-catenin, Cyclin D1, DVL2, and p-GSK3β proteins in the ALDH+ treated cells. The gene discussed is LDHA; the disease is cancer.